Imatinib Mesylate
A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.
Year introduced: 2016 (1996)
PubMed search builder options
Subheadings:
Tree Number(s): D02.065.277.456, D02.241.223.100.100.435, D02.455.426.559.389.127.085.465, D03.383.606.405, D03.383.742.349
MeSH Unique ID: D000068877
Registry Number: 8A1O1M485B
Entry Terms:
- Mesylate, Imatinib
- Imatinib Methanesulfonate
- Methanesulfonate, Imatinib
- CGP 57148
- CGP-57148
- CGP57148
- CGP57148B
- STI571
- STI-571
- STI 571
- Gleevec
- Glivec
- ST 1571
- ST1571
- Imatinib
- Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide
Pharmacologic Action: